Stimulation of angiogenesis by Ras proteins

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1654, Issue 1, 2004, Pages 23-37

  Kranenburg, Onno ^a   Gebbink, Martijn F B G ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Cyclooxygenase; Metalloprotease; Ras; Thrombospondin; Urokinase; VEGF

Indexed keywords

ANGIOGENIC FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FARNESYL DIPHOSPHATE; GELATINASE A; GELATINASE B; GERANYLGERANYL PYROPHOSPHATE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; OXYGEN; RAS PROTEIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; CAPILLARY PROLIFERATION; CARCINOGENESIS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL TRIAL; GENE EXPRESSION; GENE FUNCTION; HUMAN; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 1242337357     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2003.09.004     Document Type: Review

References (205)

1. Pulciani S., Santos E., Lauver A.V., Long L.K., Robbins K.C., Barbacid M. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:1982;2845-2849.
2. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 297:1982;474-478.
3. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. U. S. A. 79:1982;3637-3640.
4. Shimizu K., Goldfarb M., Suard Y., Perucho M., Li Y., Kamata T., Feramisco J., Stavnezer E., Fogh J., Wigler M.H. Three human transforming genes are related to the viral ras oncogenes. Proc. Natl. Acad. Sci. U. S. A. 80:1983;2112-2116.
5. Shimizu K., Goldfarb M., Perucho M., Wigler M. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc. Natl. Acad. Sci. U. S. A. 80:1983;383-387.
6. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
7. Carpenter G. The EGF receptor: a nexus for trafficking and signaling. BioEssays. 22:2000;697-707.
8. Kranenburg O., Moolenaar W.H. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene. 20:2001;1540-1546.
9. Motojima K., Urano T., Nagata Y., Shiku H., Tsunoda T., Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am. J. Gastroenterol. 86:1991;1784-1788.
10. Sagawa M., Saito Y., Fujimura S., Linnoila R.I. K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer. Br. J. Cancer. 77:1998;720-723.
11. Lemoine N.R., Mayall E.S., Wyllie F.S., Williams E.D., Goyns M., Stringer B., Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 4:1989;159-164.
12. Yunis J.J., Boot A.J., Mayer M.G., Bos J.L. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene. 4:1989;609-614.
13. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:1987;293-297.
14. Bremner R., Balmain A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell. 61:1990;407-417.
15. Kumar R., Sukumar S., Barbacid M. Activation of ras oncogenes preceding the onset of neoplasia. Science. 248:1990;1101-1104.
16. Osaka M., Matsuo S., Koh T., Sugiyama T. Specific N-ras mutation in bone marrow within 48 H of 7,12-dimethylbenz[a]anthracene treatment in Huggins-Sugiyama rat leukemogenesis. Mol. Carcinog. 16:1996;126-131.
17. Quintanilla M., Brown K., Ramsden M., Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 322:1986;78-80.
18. Sukumar S., Notario V., Martin-Zanca D., Barbacid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature. 306:1983;658-661.
19. Sukumar S., Armstrong B., Bruyntjes J.P., Leav I., Bosland M.C. Frequent activation of the Ki-ras oncogene at codon 12 in N-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Mol. Carcinog. 4:1991;362-368.
20. Zarbl H., Sukumar S., Arthur A.V., Martin-Zanca D., Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature. 315:1985;382-385.
21. Balmain A., Brown K. Oncogene activation in chemical carcinogenesis. Adv. Cancer Res. 51:1988;147-182.
22. Brown K., Quintanilla M., Ramsden M., Kerr I.B., Young S., Balmain A. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell. 46:1986;447-456.
23. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:2001;3243-3248.
24. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:2001;1111-1116.
25. Meuwissen R., Linn S.C., Van der Valk D., Mooi W.J., Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene. 20:2001;6551-6558.
26. Quaife C.J., Pinkert C.A., Ornitz D.M., Palmiter R.D., Brinster R.L. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell. 48:1987;1023-1034.
27. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W., Cordon-Cardo C., Yancopoulos G.D., DePinho R.A. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
28. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14:1995;263-277.
29. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
30. Giles F.J. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt.). 16:2002;23-29.
31. Thompson T.C., Southgate J., Kitchener G., Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell. 56:1989;917-930.
32. Balmain A., Pragnell I.B. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature. 303:1983;72-74.
33. Balmain A., Ramsden M., Bowden G.T., Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature. 307:1984;658-660.
34. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G., Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55:1995;5049-5053.
35. Brown L.F., Guidi A.J., Tognazzi K., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor and vascular stroma formation in neoplasia. Insights from in situ hybridization studies. J. Histochem. Cytochem. 46:1998;569-575.
36. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
37. Wong M.P., Cheung N., Yuen S.T., Leung S.Y., Chung L.P. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int. J. Cancer. 81:1999;845-850.
38. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
39. Manley P.W., Martiny-Baron G., Schlaeppi J.M., Wood J.M. Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs. 11:2002;1715-1736.
40. Siemeister G., Martiny-Baron G., Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev. 17:1998;241-248.
41. Ikeda N., Nakajima Y., Sho M., Adachi M., Huang C.L., Iki K., Kanehiro H., Hisanaga M., Nakano H., Miyake M. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer. 92:2001;488-499.
42. Konishi T., Huang C.L., Adachi M., Taki T., Inufusa H., Kodama K., Kohno N., Miyake M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int. J. Oncol. 16:2000;501-511.
43. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., Koller C., Estrov Z., O'Brien S., Keating M., Freireich E., Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 96:2000;2240-2245.
44. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., Manshouri T., Gidel C., O'Brien S., Keating M.J., Albitar M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 95:2002;1923-1930.
45. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Giles F.J., Rogers A., Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 99:2002;2265-2267.
46. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N., Frank D., Brownlee M., Flynn E., Parangi S., Byers H.R., Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U. S. A. 94:1997;861-866.
47. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R.S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3609-3614.
48. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:1995;4575-4580.
49. Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., Olofsson B., Joukov V., Eriksson U., Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 14:1997;2475-2483.
50. Milanini J., Vinals F., Pouyssegur J., Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273:1998;18165-18172.
51. Ross P.J., George M., Cunningham D., DiStefano F., Andreyev H.J., Workman P., Clarke P.A. Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides. Mol. Cancer Ther. 1:2001;29-41.
52. Tokunaga T., Tsuchida T., Kijima H., Okamoto K., Oshika Y., Sawa N., Ohnishi Y., Yamazaki H., Miura S., Ueyama Y., Nakamura M. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br. J. Cancer. 83:2000;833-839.
53. Maxwell P.H., Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13:2002;29-37.
54. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206.
55. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9630-9635.
56. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 20(292):2001;464-468.
57. Hur E., Chang K.Y., Lee E., Lee S.K., Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol. Pharmacol. 59:2001;1216-1224.
58. Lee E., Yim S., Lee S.K., Park H. Two transactivation domains of hypoxia-inducible factor-1alpha regulated by the MEK-1/p42/p44 MAPK pathway. Mol. Cells. 14:2002;9-15.
59. Sodhi A., Montaner S., Miyazaki H., Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287:2001;292-300.
60. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274:1999;32631-32637.
61. Jung F., Haendeler J., Hoffmann J., Reissner A., Dernbach E., Zeiher A.M., Dimmeler S. Hypoxic induction of the hypoxia-inducible factor is mediated via the adaptor protein Shc in endothelial cells. Circ. Res. 91:2002;38-45.
62. Blancher C., Moore J.W., Robertson N., Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 61:2001;7349-7355.
63. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276:2001;9519-9525.
64. Mazure N.M., Chen E.Y., Laderoute K.R., Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:1997;3322-3331.
65. Berra E., Pages G., Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19:2000;139-145.
66. Milanini-Mongiat J., Pouyssegur J., Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277:2002;20631-20639.
67. Merchant J.L., Du M., Todisco A. Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem. Biophys. Res. Commun. 19(254):1999;454-461.
68. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:1996;2746-2753.
69. Pages G., Berra E., Milanini J., Levy A.P., Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J. Biol. Chem. 275:2000;26484-26491.
70. White F.C., Benehacene A., Scheele J.S., Kamps M. VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation-evidence for divergent stabilization pathways. Growth Factors. 14:1997;199-212.
71. Sonenberg N., Gingras A.C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10:1998;268-275.
72. Gingras A.C., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann. Rev. Biochem. 68:1999;913-963.
73. Gingras A.C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1999;1422-1437.
74. Herbert T.P., Tee A.R., Proud C.G. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J. Biol. Chem. 277:2002;11591-11596.
75. Polunovsky V.A., Gingras A.C., Sonenberg N., Peterson M., Tan A., Rubins J.B., Manivel J.C., Bitterman P.B. Translational control of the antiapoptotic function of Ras. J. Biol. Chem. 275:2000;24776-24780.
76. Scott P.A., Smith K., Poulsom R., De Benedetti A., Bicknell R., Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br. J. Cancer. 77:1998;2120-2128.
77. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer. 65:1996;785-790.
78. De Benedetti A., Harris A.L. eIF4E expression in tumors: its possible role in progression of malignancies. Int. J. Biochem. Cell Biol. 31:1999;59-72.
79. Crew J.P., Fuggle S., Bicknell R., Cranston D.W., De Benedetti A., Harris A.L. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer. 82:2000;161-166.
80. Nathan C.A., Franklin S., Abreo F.W., Nassar R., De Benedetti A., Williams J., Stucker F.J. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope. 109:1999;1253-1258.
81. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer. 65:1996;785-790.
82. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., Mansour S.J., Ahn N.G., Kerbel R.S. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60:2000;490-498.
83. Mazure N.M., Chen E.Y., Yeh P., Laderoute K.R., Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56:1996;3436-3440.
84. Breier G., Blum S., Peli J., Groot M., Wild C., Risau W., Reichmann E. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int. J. Cancer. 97:2002;142-148.
85. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59:1999;1592-1598.
86. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
87. Seko Y., Tobe K., Takahashi N., Kaburagi Y., Kadowaki T., Yazaki Y. Hypoxia and hypoxia/reoxygenation activate Src family tyrosine kinases and p21ras in cultured rat cardiac myocytes. Biochem. Biophys. Res. Commun. 226:1996;530-535.
88. Li C., Jackson R.M. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am. J. Physiol., Cell Physiol. 282:2002;C227-C241.
89. Lander H.M., Ogiste J.S., Teng K.K., Novogrodsky A. p21ras as a common signaling target of reactive free radicals and cellular redox stress. J. Biol. Chem. 270:1995;21195-21198.
90. Lander H.M., Ogiste J.S., Pearce S.F., Levi R., Novogrodsky A. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J. Biol. Chem. 270:1995;7017-7020.
91. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer. 36:2000;1649-1660.
92. Ghiso N., Rohan R.M., Amano S., Garland R., Adamis A.P. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest. Ophthalmol. Visual Sci. 40:1999;1033-1039.
93. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375:1995;577-581.
94. Schafer G., Cramer T., Suske G., Kemmner W., Wiedenmann B., Hocker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem. 278:2003;8190-8198.
95. Feldkamp M.M., Lau N., Rak J., Kerbel R.S., Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer. 81:1999;118-124.
96. Xu L., Fukumura D., Jain R.K. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J. Biol. Chem. 277:2002;11368-11374.
97. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:2001;6020-6024.
98. Mettouchi A., Cabon F., Montreau N., Vernier P., Mercier G., Blangy D., Tricoire H., Vigier P., Binetruy B. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J. 13:1994;5668-5678.
99. Zabrenetzky V., Harris C.C., Steeg P.S., Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer. 59:1994;191-195.
100. Sheibani N., Frazier W.A. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett. 107:1996;45-52.
101. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6:2002;1-12.
102. Volpert O.V., Tolsma S.S., Pellerin S., Feige J.J., Chen H., Mosher D.F., Bouck N. Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Commun. 217:1995;326-332.
103. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 17:2001;25-51.
104. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 87:1990;6624-6628.
105. Filleur S., Volpert O.V., Degeorges A., Voland C., Reiher F., Clezardin P., Bouck N., Cabon F. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 15:2001;1373-1382.
106. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 93:1998;1159-1170.
107. Agah A., Kyriakides T.R., Lawler J., Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol. 161:2002;831-839.
108. Clarke N., Arenzana N., Hai T., Minden A., Prywes R. Epidermal growth factor induction of the c-jun promoter by a Rac pathway. Mol. Cell. Biol. 18:1998;1065-1073.
109. Kraemer M., Tournaire R., Dejong V., Montreau N., Briane D., Derbin C., Binetruy B. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ. 10:1999;193-200.
110. Gutierrez L.S., Suckow M., Lawler J., Ploplis V.A., Castellino F.J. Thrombospondin 1 - a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis. 24:2003;199-207.
111. Hawighorst T., Velasco P., Streit M., Hong Y.K., Kyriakides T.R., Brown L.F., Bornstein P., Detmar M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J. 20:2001;2631-2640.
112. Hawighorst T., Oura H., Streit M., Janes L., Nguyen L., Brown L.F., Oliver G., Jackson D.G., Detmar M. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene. 21:2002;7945-7956.
113. O'Byrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer. 85:2001;473-483.
114. Dalgleish A.G., O'Byrne K.J. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv. Cancer Res. 84:2002;231-276.
115. Prescott S.M., Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta. 1470:2000;M69-M78.
116. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1997;1-20.
117. Giardiello F.M., Offerhaus G.J., DuBois R.N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer. 31A:1995;1071-1076.
118. DuBois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
119. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:2003;96-102.
120. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:2000;3-21.
121. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1999;1418-1423.
122. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 90:1998;1609-1620.
123. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
124. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
125. Tiano H.F., Loftin C.D., Akunda J., Lee C.A., Spalding J., Sessoms A., Dunson D.B., Rogan E.G., Morham S.G., Smart R.C., Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:2002;3395-3401.
126. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708.
127. Jones M.K., Szabo I.L., Kawanaka H., Husain S.S., Tarnawski A.S. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J. 16:2002;264-266.
128. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:1999;451-459.
129. Elder D.J., Paraskeva C. NSAIDs to prevent colorectal cancer: a question of sensitivity. Gastroenterology. 113:1997;1999-2003.
130. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127:2001;411-417.
131. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
132. Dormond O., Foletti A., Paroz C., Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 7:2001;1041-1047.
133. Hoper M.M., Voelkel N.F., Bates T.O., Allard J.D., Horan M., Shepherd D., Tuder R.M. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am. J. Respir. Cell Mol. Biol. 17:1997;748-756.
134. Form D.M., Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172:1983;214-218.
135. Ziche M., Jones J., Gullino P.M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:1982;475-482.
136. Spisni E., Manica F., Tomasi V. Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot. Essent. Fat. Acids. 47:1992;111-115.
137. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59:1999;4574-4577.
138. Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., Rodan B. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496.
139. Hoper M.M., Voelkel N.F., Bates T.O., Allard J.D., Horan M., Shepherd D., Tuder R.M. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am. J. Respir. Cell Mol. Biol. 17:1997;748-756.
140. Pueyo M.E., Chen Y., D'Angelo G., Michel J.B. Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells. Exp. Cell Res. 238:1998;354-358.
141. Cheng T., Cao W., Wen R., Steinberg R.H., LaVail M.M. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest. Ophthalmol. Visual Sci. 39:1998;581-591.
142. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 7:2001;1048-1051.
143. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594.
144. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., Murata T., Yoshimura H., Narumiya S., Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 20(197):2003;221-232.
145. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., Narumiya S., Taketo M.M. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62:2002;506-511.
146. Howe L.R., Crawford H.C., Subbaramaiah K., Hassell J.A., Dannenberg A.J., Brown A.M. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem. 276:2001;20108-20115.
147. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shiseki M., Miura K., Harris C.C. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63:2003;728-734.
148. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915.
149. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277:2002;18649-18657.
150. Ji Y.S., Xu Q., Schmedtje J.F. Jr. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ. Res. 83:1998;295-304.
151. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., DeVito B., Weksler B.B., Dannenberg A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
152. Sheng H., Williams C.S., Shao J., Liang P., DuBois R.N., Beauchamp R.D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J. Biol. Chem. 273:1998;22120-22127.
153. Xie W., Fletcher B.S., Andersen R.D., Herschman H.R. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol. Cell. Biol. 14:1994;6531-6539.
154. Xie W., Herschman H.R. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J. Biol. Chem. 270:1995;27622-27628.
155. Xie W., Herschman H.R. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J. Biol. Chem. 271:1996;31742-31748.
156. Reddy S.T., Wadleigh D.J., Herschman H.R. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J. Biol. Chem. 275:2000;3107-3113.
157. O'Hagan R.C., Tozer R.G., Symons M., McCormick F., Hassell J.A. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene. 19(13):1996;1323-1333.
158. Lengyel E., Stepp E., Gum R., Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem. 270:1995;23007-23012.
159. Silberman S., Janulis M., Schultz R.M. Characterization of downstream Ras signals that induce alternative protease-dependent invasive phenotypes. J. Biol. Chem. 272:1997;5927-5935.
160. Sheng H., Shao J., DuBois R.N. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 61:2001;2670-2675.
161. Howe L.R., Crawford H.C., Subbaramaiah K., Hassell J.A., Dannenberg A.J., Brown A.M. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem. 276:2001;20108-20115.
162. Giles F.J., Kantarjian H.M., Bekele B.N., Cortes J.E., Faderl S., Thomas D.A., Manshouri T., Rogers A., Keating M.J., Talpaz M., O'Brien S., Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br. J. Haematol. 119:2002;38-45.
163. Schmedtje J.F. Jr., Ji Y.S., Liu W.L., DuBois R.N., Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272:1997;601-608.
164. Williams C.S., DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 270:1996;G393-G400.
165. Ise K., Nakamura K., Nakao K., Shimizu S., Harada H., Ichise T., Miyoshi J., Gondo Y., Ishikawa T., Aiba A., Katsuki M. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene. 19:2000;2951-2956.
166. Berns A. Turning on tumors to study cancer progression. Nat. Med. 5:1999;989-990.
167. Berns A. Cancer. Improved mouse models. Nature. 410:2001;1043-1044.
168. Brunner G., Pohl J., Erkell L.J., Radler-Pohl A., Schirrmacher V. Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene. J. Cancer Res. Clin. Oncol. 115:1989;139-144.
169. Testa J.E., Medcalf R.L., Cajot J.F., Schleuning W.D., Sordat B. Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. Int. J. Cancer. 43:1989;816-822.
170. Gum R., Lengyel E., Juarez J., Chen J.H., Sato H., Seiki M., Boyd D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271:1996;10672-10680.
171. Sato H., Kida Y., Mai M., Endo Y., Sasaki T., Tanaka J., Seiki M. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 7:1992;77-83.
172. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21:2001;1104-1117.
173. Duffy M.J., Maguire T.M., McDermott E.W., O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol. 71:1999;130-135.
174. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 86:2001;324-333.
175. Ellis V., Pyke C., Eriksen J., Solberg H., Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N.Y. Acad. Sci. 667:1992;13-31.
176. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb. Haemost. 82:1999;298-304.
177. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev., Mol. Cell Biol. 3:2002;932-943.
178. Ried S., Jager C., Jeffers M., Vande Woude G.F., Graeff H., Schmitt M., Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J. Biol. Chem. 274:1999;16377-16386.
179. Wolthuis R.M., Bos J.L. Ras caught in another affair: the exchange factors for Ral. Curr. Opin. Genet. Dev. 9:1999;112-117.
180. Aguirre-Ghiso J.A., Frankel P., Farias E.F., Lu Z., Jiang H., Olsen A., Feig L.A., Kier Joffe E.B., Foster D.A. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene. 19(18):1999;4718-4725.
181. Yang J.Q., Zhao W., Duan H., Robbins M.E., Buettner G.R., Oberley L.W., Domann F.E. v-Ha-RaS oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-kappaB. Free Radic. Biol. Med. 31:2001;520-529.
182. Jiang Y., Muschel R.J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res. 62:2002;1910-1914.
183. Carmeliet P., Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. 91:1998;255-285.
184. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267:1992;26031-26037.
185. Rifkin D.B., Moscatelli D., Bizik J., Quarto N., Blei F., Dennis P., Flaumenhaft R., Mignatti P. Growth factor control of extracellular proteolysis. Cell Differ. Dev. 32:1990;313-318.
186. Rifkin D.B., Mazzieri R., Munger J.S., Noguera I., Sung J. Proteolytic control of growth factor availability. APMIS. 107:1999;80-85.
187. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10:2000;415-433.
188. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744.
189. Berkelhammer J., Oxenhandler R.W., Hook R.R. Jr., Hennessy J.M. Development of a new melanoma model in C57BL/6 mice. Cancer Res. 42:1982;3157-3163.
190. Walker G.J., Hayward N.K. Pathways to melanoma development: lessons from the mouse. J. Invest. Dermatol. 119:2002;783-792.
191. Shapiro R.L., Duquette J.G., Roses D.F., Nunes I., Harris M.N., Kamino H., Wilson E.L., Rifkin D.B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56:1996;3597-3604.
192. Park H.J., Kong D., Iruela-Arispe L., Begley U., Tang D., Galper J.B. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91:2002;143-150.
193. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T., Vannier J.P., Soria J., Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 495:2001;159-166.
194. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J.P., Soria J., Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 22:2002;623-629.
195. Feleszko W., Balkowiec E.Z., Sieberth E., Marczak M., Dabrowska A., Giermasz A., Czajka A., Jakobisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int. J. Cancer. 81:1999;560-567.
196. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 18:1999;7514-7526.
197. Gu W.Z., Tahir S.K., Wang Y.C., Zhang H.C., Cherian S.P., O'Connor S., Leal J.A., Rosenberg S.H., Ng S.C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer. 35:1999;1394-1401.
198. Charvat S., Duchesne M., Parvaz P., Chignol M.C., Schmitt D., Serres M. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res. 19:1999;557-561.
199. Tahir S.K., Gu W.Z., Zhang H.C., Leal J., Lee J.Y., Kovar P., Saeed B., Cherian S.P., Devine E., Cohen J., Warner R., Wang Y.C., Stout D., Arendsen D.L., Rosenberg S., Ng S.C. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur. J. Cancer. 36:2000;1161-1170.
200. Zhang B., Prendergast G.C., Fenton R.G. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 62:2002;450-458.
201. Karp J.E., Lancet J.E., Kaufmann S.H., End D.W., Wright J.J., Bol K., Horak I., Tidwell M.L., Liesveld J., Kottke T.J., Ange D., Buddharaju L., Gojo I., Highsmith W.E., Belly R.T., Hohl R.J., Rybak M.E., Thibault A., Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369.
202. Karp J.E., Kaufmann S.H., Adjei A.A., Lancet J.E., Wright J.J., End D.W. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 13:2001;470-476.
203. Feldkamp M.M., Lau N., Roncari L., Guha A. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 61:2001;4425-4431.
204. Lebowitz P.F., Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17:1998;1439-1445.
205. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta. 1333:1997;F51-F71.